Videos

A panelist discusses how the newly FDA-approved intranasal epinephrine (Neffy) delivers blood concentrations and physiological responses comparable or superior to traditional intramuscular epinephrine administration methods.

A panelist discusses how current guidance has evolved to no longer require emergency department visits for all epinephrine uses, particularly when patients experience prompt and complete resolution of symptoms after administration.

A panelist discusses how patient uncertainty about when to administer epinephrine and reluctance to use autoinjectors are major barriers to timely treatment, with over 40% not filling their prescriptions and 55% to 60% not consistently carrying their devices.

A panelist discusses how epinephrine is definitively the first-line treatment for anaphylaxis regardless of severity, emphasizing that delayed administration is associated with poor outcomes, including abnormal vital signs and increased risk of hospitalization.

A panelist discusses how anaphylaxis should be defined and treated promptly with epinephrine, highlighting the concerning statistic that not all patients who experience anaphylaxis receive this critical first-line treatment.

A panelist discusses how simplifying treatment regimens, using nonsteroidal options, and fostering collaboration between primary care and dermatology can improve patient adherence and outcomes while emphasizing the importance of careful consideration when transitioning to systemic treatments or biologics due to safety concerns and patient needs.

A panelist discusses how the ADORING trial for tapinarof demonstrated good efficacy and safety, but emphasizes that treatment choices for atopic dermatitis depend on patient needs, preferences, and the specific characteristics of their condition, with factors like speed of action, safety, and adherence playing key roles in decision-making.

A panelist discusses how the real-world use of crisaborole, roflumilast, and ruxolitinib for atopic dermatitis reveals differing tolerability and efficacy, with roflumilast standing out for its superior results and ease of use while ruxolitinib is limited by safety concerns for larger areas of the body.

The speaker discusses the challenges of treating patients with topical steroid withdrawal, emphasizing the need for careful steroid reintroduction and responsible use while also exploring newer nonsteroidal treatments for atopic dermatitis and the barriers to access due to high costs and limited comparative effectiveness data.

A panelist discusses how patients cycling through numerous topical treatments, often without success, signals the need for treatment escalation or specialist referral, while emphasizing the risks and proper use of topical corticosteroids and calcineurin inhibitors in managing chronic dermatological conditions.

A panelist discusses how structured assessment tools like the itch Numeric Rating Scale, combined with a flexible, patient-centered approach to topical therapies—including both traditional steroids and newer non-steroidal agents—can improve atopic dermatitis management in primary care by enhancing treatment tracking, patient education, and access to appropriate care.

A panelist discusses how diagnosing and assessing atopic dermatitis across diverse skin types in primary care requires visual familiarity, patient-reported outcomes like itch severity, and practical tools such as body surface area and Investigator’s Global Assessment, emphasizing that effective management depends on combining clinical observation with patient experience.

A panelist discusses how recognizing the diverse presentations and patient demographics of atopic dermatitis—especially adult-onset cases and common mimics like scabies—is essential for accurate diagnosis and management in primary care, with an emphasis on clinical assessment over biopsy and the importance of cultural competence in dermatologic evaluation.

A panelist discusses how a fresh approach to atopic dermatitis management in primary care emphasizes early recognition, appropriate use of new topical therapies, and collaboration with dermatologists to address the disease’s diverse presentations and chronic course.

Panelists discuss how choosing topical treatments requires individualized therapy considering factors such as affected body areas, disease severity, patient age, formulation preferences, and insurance coverage.

Panelists discuss how roflumilast demonstrated good efficacy with 56% to 57% of patients achieving an Investigator’s Global Assessment (IGA) score of 0 or 1 after long-term use, making it effective for maintenance therapy with good tolerability.

Panelists discuss how newer nonsteroidal topical treatments like phosphodiesterase-4 inhibitors (crisaborole and roflumilast), JAK inhibitors (ruxolitinib), and aryl hydrocarbon receptor agonists (tapinarof) are expanding options for atopic dermatitis treatment.

Panelists discuss how long-term use of topical steroids is prevalent with 50% of patients using them 15 to 30 days per month, leading to concerns about adverse effects, including topical steroid withdrawal syndrome.

Panelists discuss how even mild atopic dermatitis can significantly impact quality of life, with 11% of patients with mild symptoms reporting moderate to large impact on their daily functioning.

Panelists discuss how topical steroids should be used intermittently with scheduled breaks to prevent adverse effects like skin atrophy, striae, and telangiectasias.

Panelists discuss how various assessment tools like the IGA, EASI score, and BSA are used to determine the severity of atopic dermatitis and document findings for insurance purposes.

Panelists discuss how atopic dermatitis (AD) affects approximately 7% of adults, has increased by 3% to 5% over the last 5 years, and impacts different body regions depending on age groups.

Panelists discuss how atopic dermatitis presents with red, scaly, itchy, dry, and inflamed skin and is commonly diagnosed in childhood, although it can occur at any age, with frequent flares and comorbid conditions like asthma and allergies.

A panelist discusses how contemporary therapeutic approaches enable successful management of atopic dermatitis through examination of real-world patient cases that demonstrate effective disease control strategies using the latest treatment options.